Edward A Neuwelt

List of Publications by Year in Descending Order

154 papers	10,448 citations	54 h-index	99 g-index
165 ext. papers	11,580 ext. citations	5 avg, IF	5.83 L-index

#	Paper	IF	Citations
154	Diagnostic performance of DSC perfusion MRI to distinguish tumor progression and treatment-related changes: a systematic review and meta-analysis.. *Neuro-Oncology Advances*, **2022**, 4, vdac027	0.9	
153	Advances in Intraarterial Chemotherapy Delivery Strategies and Blood-Brain Barrier Disruption.. *Neurosurgery Clinics of North America*, **2022**, 33, 219-223	4	0
152	The clinical heterogeneity of entirely nonenhancing CNS lymphoma: a case series. *CNS Oncology*, **2021**, 10, CNS67	4	2
151	Blood-brain barrier opening by intracarotid artery hyperosmolar mannitol induces sterile inflammatory and innate immune responses. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	7
150	Risk Factors and Disease Course for Blood-Brain Barrier Disruption-Associated Maculopathy. *JAMA Ophthalmology*, **2021**, 139, 143-149	3.9	2
149	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). *Neuro-Oncology*, **2021**, 23, 1056-1071	1	16
148	Long-Term Outcomes of Intra-Arterial Chemotherapy for Progressive or Unresectable Pilocytic Astrocytomas: Case Studies. *Neurosurgery*, **2021**, 88, E336-E342	3.2	2
147	Distinguishing Extravascular from Intravascular Ferumoxytol Pools within the Brain: Proof of Concept in Patients with Treated Glioblastoma. *American Journal of Neuroradiology*, **2020**, 41, 1193-1200	4.4	5
146	Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma. *Journal of Neuro-Oncology*, **2020**, 147, 171-176	4.8	5
145	Safety Profile of Maintenance Obinutuzumab in Patients with Primary CNS Lymphoma in Complete Response. *Blood*, **2020**, 136, 12-12	2.2	
144	Maculopathy Associated With Osmotic Blood- Brain Barrier Disruption and Chemotherapy in Patients With Primary CNS Lymphoma. *Ophthalmic Surgery Lasers and Imaging Retina*, **2020**, 51, S5-S12	1.4	2
143	Ferumoxytol-Enhanced MRI Is Not Inferior to Gadolinium-Enhanced MRI in Detecting Intracranial Metastatic Disease and Metastasis Size. *American Journal of Roentgenology*, **2020**, 215, 1436-1442	5.4	1
142	Transcriptional signatures in histologic structures within glioblastoma tumors may predict personalized drug sensitivity and survival. *Neuro-Oncology Advances*, **2020**, 2, vdaa093	0.9	2
141	Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. *Leukemia and Lymphoma*, **2019**, 60, 515-518	1.9	18
140	Pharmacokinetics of Drug Delivery Past the BloodBrain Barrier **2019**, 57-72		1
139	BloodBrain Barrier Disruption **2019**, 193-208		
138	Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression. *Neuro-Oncology*, **2019**, 21, 517-526	1	13

137	Neurovascular Unit: Basic and Clinical Imaging with Emphasis on Advantages of Ferumoxytol. *Neurosurgery*, **2018**, 82, 770-780	3.2	25
136	Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care. *Journal of Magnetic Resonance Imaging*, **2018**, 48, 441-448	5.6	8
135	Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. *New England Journal of Medicine*, **2018**, 378, 2376-2385	59.2	127
134	Quantitative comparison of delayed ferumoxytol T enhancement with immediate gadoteridol enhancement in high grade gliomas. *Magnetic Resonance in Medicine*, **2018**, 80, 224-230	4.4	7
133	MBCL-48. HEARING CHEMOPROTECTION WITH SODIUM THIOSULFATE (STS) IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH STANDARD RISK MEDULLOBLASTOMA. *Neuro-Oncology* , **2018**, 20, i127-i128	1	1
132	Blood-Brain Barrier Disruption Chemotherapy **2018**, 145-153		2
131	Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. *Journal of Clinical Oncology*, **2017**, 35, 440-445	2.2	47
130	Comprehensive Review of the ThinkFirst Injury Prevention Programs: A 30-Year Success Story for Organized Neurosurgery. *Neurosurgery*, **2017**, 81, 416-421	3.2	8
129	What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent. *American Journal of Neuroradiology*, **2017**, 38, 1297-1302	4.4	35
128	Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. *Kidney International*, **2017**, 92, 47-66	9.9	168
127	Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet Oncology, The*, **2017**, 18, 63-74	21.7	99
126	The Translational Significance of the Neurovascular Unit. *Journal of Biological Chemistry*, **2017**, 292, 762-770	3.4	156
125	Pseudo-extravasation rate constant of dynamic susceptibility contrast-MRI determined from pharmacokinetic first principles. *NMR in Biomedicine*, **2017**, 30, e3797	4.4	
124	Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease. *Fluids and Barriers of the CNS*, **2017**, 14, 16	7	16
123	Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto- and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiency. *Fluids and Barriers of the CNS*, **2017**, 14, 26	7	9
122	High β Integrin Level of Cancer Cells Is Associated with Development of Brain Metastasis in Athymic Rats. *Anticancer Research*, **2017**, 37, 4029-4040	2.3	16
121	Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. *Journal of Neuro-Oncology*, **2016**, 126, 447-54	4.8	13
120	Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults. *Investigative Radiology*, **2016**, 51, 221-227	10.1	59

119	Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases: a pilot study with immunohistochemical observations. *Journal of Neuro-Oncology*, **2016**, 129, 301-9	4.8	13
118	Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab. *Fluids and Barriers of the CNS*, **2016**, 13, 23	7	4
117	Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2016**, 12, 1535-42	6	28
116	Unsanctifying the sanctuary: challenges and opportunities with brain metastases. *Neuro-Oncology*, **2015**, 17, 639-51	1	40
115	TR-15USE OF IV N-ACETYLCYSTEINE IN COMBINATION WITH SODIUM THIOSULFATE FOR PREVENTION OF OTOTOXICITY IN PEDIATRIC PATIENTS. *Neuro-Oncology*, **2015**, 17, iii40-iii40	1	78
114	N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models. *Journal of Neuro-Oncology*, **2015**, 121, 433-40	4.8	25
113	Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis. *Fluids and Barriers of the CNS*, **2015**, 12, 5	7	21
112	Interactions between β-Integrin and HER2 and Their Role in the Invasive Phenotype of Breast Cancer Cells In Vitro and in Rat Brain. *PLoS ONE*, **2015**, 10, e0131842	3.7	13
111	Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances. *Advances in Pharmacology*, **2014**, 71, 203-43	5.7	59
110	Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. *Neuro-Oncology*, **2014**, 16, 1146-54	1	74
109	Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. *CNS Oncology*, **2014**, 3, 389-400	4	25
108	SIOPEL 6: A multicenter open-label randomized phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard-risk hepatoblastoma (SR-HB).. *Journal of Clinical Oncology*, **2014**, 32, TPS10094-TPS10094	2.2	3
107	Oligodendroglial Tumors: Intra-arterial Chemotherapy. *Tumors of the Central Nervous System*, **2014**, 15-22		
106	Inhibition of SUR1 decreases the vascular permeability of cerebral metastases. *Neoplasia*, **2013**, 15, 535-43	6.4	37
105	Feasibility and potential role of ferumoxytol-enhanced neuroimaging in HIV-associated neurocognitive disorder. *Journal of NeuroVirology*, **2013**, 19, 601-5	3.9	5
104	Immunologic privilege in the central nervous system and the blood-brain barrier. *Journal of Cerebral Blood Flow and Metabolism*, **2013**, 33, 13-21	7.3	188
103	Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery. *Journal of Clinical Oncology*, **2013**, 31, 4026-7	2.2	18
102	Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. *Radiology*, **2013**, 266, 842-52	20.5	133

101	The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma. *Journal of Neurosurgery: Pediatrics*, **2013**, 11, 60-7	2.1	6
100	Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL. *Neurology*, **2013**, 81, 256-63	6.5	49
99	High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle. *Journal of Cerebral Blood Flow and Metabolism*, **2013**, 33, 780-6	7.3	79
98	Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. *Neurology*, **2013**, 81, 84-92	6.5	103
97	Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma. *Anticancer Research*, **2013**, 33, 2391-400	2.3	16
96	Targeting β-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. *Journal of Neuro-Oncology*, **2012**, 110, 27-36	4.8	41
95	Ferumoxytol-enhanced MRI to Image Inflammation within Human Brain Arteriovenous Malformations: A Pilot Investigation. *Translational Stroke Research*, **2012**, 3, 166-73	7.8	41
94	Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. *Journal of Neuro-Oncology*, **2012**, 109, 105-14	4.8	36
93	Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. *Journal of Clinical Oncology*, **2012**, 30, 2408-17	2.2	229
92	Macrophage imaging within human cerebral aneurysms wall using ferumoxytol-enhanced MRI: a pilot study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 1032-8	9.4	88
91	Engaging neuroscience to advance translational research in brain barrier biology. *Nature Reviews Neuroscience*, **2011**, 12, 169-82	13.5	418
90	Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. *Pituitary*, **2011**, 14, 80-91	4.3	50
89	Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. *Journal of Neuro-Oncology*, **2011**, 103, 353-60	4.8	11
88	Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. *International Journal of Radiation Oncology Biology Physics*, **2011**, 79, 514-23	4	120
87	Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. *American Journal of Roentgenology*, **2011**, 197, 981-8	5.4	53
86	Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol. *Radiology*, **2011**, 261, 796-804	20.5	41
85	Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma. *Clinical Cancer Research*, **2011**, 17, 2207-15	12.9	24
84	The paradoxical effect of bevacizumab in the therapy of malignant gliomas. *Neurology*, **2011**, 76, 87-93	6.5	73

83	MRI using ferumoxytol improves the visualization of central nervous system vascular malformations. *Stroke*, **2011**, 42, 1581-8	6.7	62
82	Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. *Neuro-Oncology*, **2011**, 13, 251-60	1	43
81	Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. *Neuro-Oncology*, **2011**, 13, 51-60	1	33
80	Magnetic Resonance Imaging of Brain Tumors Using Iron Oxide Nanoparticles **2011**, 297-304		
79	Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. *Journal of Cerebral Blood Flow and Metabolism*, **2010**, 30, 15-35	7.3	374
78	Critical need for international consensus on ototoxicity assessment criteria. *Journal of Clinical Oncology*, **2010**, 28, 1630-2	2.2	30
77	Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. *Neurosurgery*, **2010**, 67, 87-93	3.2	20
76	Enhanced Delivery of Rituximab In Combination with Methotrexate-Based Blood-Brain Barrier Disruption for Patients with Newly Diagnosed Primary CNS Lymphoma.. *Blood*, **2010**, 116, 2792-2792	2.2	1
75	Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. *Neurosurgery*, **2010**, 66, 48-58; discussion 58	3.2	37
74	Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. *Journal of Clinical Oncology*, **2009**, 27, 3503-9	2.2	184
73	Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. *Neuro-Oncology*, **2009**, 11, 503-13	1	14
72	Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. *Neuro-Oncology*, **2009**, 11, 142-50	1	29
71	Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. *Journal of Cerebral Blood Flow and Metabolism*, **2009**, 29, 853-60	7.3	70
70	Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. *Neoplasia*, **2009**, 11, 187-95	6.4	39
69	Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. *Neoplasia*, **2009**, 11, 1003-11	6.4	25
68	Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?. *Kidney International*, **2009**, 75, 465-74	9.9	200
67	Strategies to advance translational research into brain barriers. *Lancet Neurology, The*, **2008**, 7, 84-96	24.1	370
66	N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials. *Journal of Vascular and Interventional Radiology*, **2008**, 19, 309-18	2.4	22

65	Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. *Clinical Cancer Research*, **2008**, 14, 533-40	12.9	38
64	Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. *Blood*, **2008**, 111, 1085-93	9.3	89
63	Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. *Cancer Chemotherapy and Pharmacology*, **2008**, 62, 235-41	3.5	80
62	Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. *Cancer*, **2008**, 112, 581-8	6.4	45
61	Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. *Leukemia and Lymphoma*, **2007**, 48, 1712-20	1.9	36
60	Chemotherapy delivery issues in central nervous system malignancy: a reality check. *Journal of Clinical Oncology*, **2007**, 25, 2295-305	2.2	316
59	Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. *Journal of Clinical Oncology*, **2007**, 25, 1190-5	2.2	150
58	Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma. *Clinical Cancer Research*, **2007**, 13, 2504-11	12.9	15
57	In vivo leukocyte labeling with intravenous ferumoxides/protamine sulfate complex and in vitro characterization for cellular magnetic resonance imaging. *American Journal of Physiology - Cell Physiology*, **2007**, 293, C1698-708	5.4	57
56	The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. *Neurosurgery*, **2007**, 60, 601-11; discussion 611-2	3.2	147
55	BloodBrain Barrier Disruption Chemotherapy **2006**, 262-273		2
54	Implications of the blood-brain barrier in primary central nervous system lymphoma. *Neurosurgical Focus*, **2006**, 21, E11	4.2	23
53	Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. *Pediatric Blood and Cancer*, **2006**, 47, 174-82	3	41
52	The treatment of brain metastasis from breast cancer, role of blood-brain barrier disruption and early experience with trastuzumab. *Therapy: Open Access in Clinical Medicine*, **2006**, 3, 97-112		2
51	The treatment of brain metastasis from breast cancer, role of bloodBrain barrier disruption and early experience with trastuzumab. *Therapy: Open Access in Clinical Medicine*, **2006**, 3, 97-112		1
50	Imaging, Distribution, and Toxicity of Superparamagnetic Iron Oxide Magnetic Resonance Nanoparticles in the Rat Brain and Intracerebral Tumor. *Neurosurgery*, **2005**, 57, 785-796	3.2	166
49	Imaging brain tumors with ferumoxtran-10, a nanoparticle magnetic resonance contrast agent. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 871-882		22
48	Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. *Journal of Clinical Oncology*, **2005**, 23, 8588-96	2.2	355

47	Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. *Journal of Clinical Oncology*, **2005**, 23, 5034-43	2.2	575
46	Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 314, 1052-8	4.7	169
45	The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 312, 424-31	4.7	160
44	Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. *American Journal of Neuroradiology*, **2005**, 26, 258-65	4.4	37
43	An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. *American Journal of Neuroradiology*, **2005**, 26, 2290-300	4.4	55
42	Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10. *American Journal of Neuroradiology*, **2005**, 26, 1084-8	4.4	27
41	Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. *Neurosurgery*, **2005**, 57, 785-96; discussion 785-96	3.2	72
40	Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 309, 594-9	4.7	48
39	Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. *Hearing Research*, **2004**, 193, 25-30	3.9	98
38	Mechanisms of disease: the blood-brain barrier. *Neurosurgery*, **2004**, 54, 131-40; discussion 141-2	3.2	238
37	Primary Central Nervous System Lymphoma of T Cell Origin: A Descriptive Analysis of 45 Cases from the International PCNSL Collaborative Group.. *Blood*, **2004**, 104, 1372-1372	2.2	
36	Current status and future of relapsed primary central nervous system lymphoma (PCNSL). *Leukemia and Lymphoma*, **2003**, 44, 627-33	1.9	50
35	Effect of Antigenic Heterogeneity on the Efficacy of Enhanced Delivery of Antibody-targeted Chemotherapy in a Human Lung Cancer Intracerebral Xenograft Model in Rats. *Neurosurgery*, **2003**, 53, 1406-1413	3.2	8
34	BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models. *Journal of Neuro-Oncology*, **2003**, 65, 49-62	4.8	32
33	Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and future directions. *Current Neurology and Neuroscience Reports*, **2002**, 2, 216-24	6.6	31
32	Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. *Ophthalmology*, **2002**, 109, 1709-16	7.3	235
31	Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. *American Journal of Neuroradiology*, **2002**, 23, 510-9	4.4	111
30	Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium. *Clinical Cancer Research*, **2002**, 8, 1702-9	12.9	17

29	Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model. *International Journal of Radiation Oncology Biology Physics*, **2001**, 51, 1045-9	4	11
28	Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. *Neurosurgery*, **2001**, 48, 1033-40; discussion 1040-1	3.2	60
27	Association of Total Dose Intensity of Chemotherapy in Primary Central Nervous System Lymphoma (Human Non-Acquired Immunodeficiency Syndrome) and Survival. *Neurosurgery*, **2001**, 48, 1033-1041	3.2	21
26	Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. *Cancer*, **2000**, 88, 637-47	6.4	302
25	Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. *Neurosurgery*, **2000**, 46, 704-9	3.2	51
24	Cognitive Outcomes and Long-term Follow-up Results after Enhanced Chemotherapy Delivery for Primary Central Nervous System Lymphoma. *Neurosurgery*, **2000**, 46, 51-61	3.2	160
23	Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model. *Neurosurgery*, **2000**, 47, 199-207	3.2	22
22	Unexpected Neurotoxicity of Etoposide Phosphate Administered in Combination with Other Chemotherapeutic Agents after Blood-Brain Barrier Modification to Enhance Delivery, Using Propofol for General Anesthesia, in a Rat Model. *Neurosurgery*, **2000**, 47, 199-207	3.2	16
21	Cognitive Outcomes and Long-term Follow-up Results after Enhanced Chemotherapy Delivery for Primary Central Nervous System Lymphoma. *Neurosurgery*, **2000**, 51-61	3.2	108
20	Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors **2000**, 88, 637		1
19	The Influence of Anesthetic Choice, PaCO2, and Other Factors on Osmotic Blood-Brain Barrier Disruption in Rats with Brain Tumor Xenografts. *Anesthesia and Analgesia*, **1999**, 88, 559-567	3.9	47
18	The influence of anesthetic choice, PaCO2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts. *Anesthesia and Analgesia*, **1999**, 88, 559-67	3.9	45
17	Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. *Neurosurgery*, **1998**, 43, 879-86; discussion 886-9	3.2	96
16	Atypical central nervous system lymphoma at the cranial base: report of four cases. *Neurosurgery*, **1998**, 43, 613-5; discussion 615-6	3.2	42
15	Long-term toxicity and neuropathology associated with the sequencing of cranial irradiation and enhanced chemotherapy delivery. *Neurosurgery*, **1997**, 40, 1034-40; discussion 1040-2	3.2	17
14	Increasing Volume of Distribution to the Brain with Interstiti; Infusion: Dose, Rather Than Convection, Might Be the Most Important Factor. *Neurosurgery*, **1996**, 38, 746-754	3.2	101
13	Increasing Volume of Distribution to the Brain with Interstitial Infusion: Dose, Rather Than Convection, Might Be the Most Important Factor. *Neurosurgery*, **1996**, 746-754	3.2	13
12	Local and global gene therapy in the central nervous system. *Behavioral and Brain Sciences*, **1995**, 18, 76-78	0.9	

11	Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. *Neurosurgery*, **1995**, 37, 17-27; discussion 27-8	3.2	92
10	Delivery of Virus-sized Iron Oxide Particles to Rodent CNS Neurons. *Neurosurgery*, **1994**, 34, 777-784	3.2	158
9	Delivery of virus-sized iron oxide particles to rodent CNS neurons. *Neurosurgery*, **1994**, 34, 777-84	3.2	113
8	Evaluation of a program to prevent head and spinal cord injuries: a comparison between middle school and high school. *Neurosurgery*, **1992**, 31, 557-61; discussion 561-2	3.2	20
7	Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy. *Neurosurgery*, **1992**, 30, 23-9	3.2	27
6	The Effects of Anesthesia on Osmotic Blood-Brain Barrier Disruption. *Neurosurgery*, **1990**, 26, 268-277	3.2	38
5	Blood-Brain Barrier Disruption in the Treatment of Brain Tumors **1989**, 195-261		22
4	Developments in the diagnosis and treatment of primary CNS lymphoma. A prospective series. *Cancer*, **1986**, 58, 1609-20	6.4	111
3	Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. *Annals of Neurology*, **1983**, 14, 316-24	9.4	108
2	Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening. *Neurosurgery*, **1983**, 12, 662-71	3.2	93
1	Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog. *Neurosurgery*, **1980**, 7, 36-43	3.2	67